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6.6), both p< 0.05. A greater proportion of schizophrenia caregivers reported at 
least one emergency room visit (26.1% vs. 20.2%) and hospitalization (20.4% vs. 
14.3%) than other caregivers, both p< 0.05. No significant difference was found 
on work-related impairment, probably due to the small sample of employed 
respondents. ConClusions: Schizophrenia caregivers reported greater activity 
impairment and more resource use than non-caregivers and caregivers of adults 
with other conditions. Better family and social support systems may help reduce 
the burden for schizophrenia caregivers.
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Medication Usage Pattern, HealtH resoUrce Utilization and 
econoMic BUrden for Patients witH Mdd in Beijing, cHina
Zhang H.1, Yue L.1, Chen Y.1, Ding H.2, Zhao K.3, Montgomery W.4
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objeCtives: To investigate medication usage patterns, health care resource 
utilization and direct medical costs of patients with Major Depressive Disorder 
(MDD) in Beijing, China. Methods: Data were randomly extracted from Beijing 
Urban Employee Basic Medical Insurance Database. Patients who were aged ≥ 18 
years, with at least 1 primary diagnosis of MDD and 12-month continuous enroll-
ment after their first observed MDD diagnosis between 2012 and 2013 were identi-
fied. Those with a diagnosis of schizophrenia, bipolar disorder or cancer within the 
study period were excluded. Descriptive statistics were used to describe patient 
profiles, medication usage, health care resource utilization and costs. Results: 
A total of 8484 patients were included with mean (±SD) age of 57.15 (±15.34) 
years, 63.02% female and 94.47% having co-morbidities. 71.35% of patients were 
treated with antidepressant medications, including 60.53% of patients with SSRIs, 
followed by NaSSA (8.96%) and SNRIs (8.26%). Concomitant medications were 
prescribed for 76.78% of patients. Only 0.42% of patients experienced ≥ 1 MDD-
related hospitalizations during the 1-year follow up and the average annual num-
ber of hospitalization was 1.22 (±0.64) for those hospitalized patients. The length 
of stay was 33.38 (±30.6) days per hospitalization and 36.61 (±40.04) days per 
patient-year. All patients had ≥ 1 MDD-related outpatient visits. The mean annual 
number of outpatient visits was 3.06 (±2.99). The mean annual direct medical 
cost for all MDD patients was 1694.05 (±2513.71) RMB with 48.54% for antidepres-
sant medications, and that for hospitalized patients was 21290.97 (±16121.61) 
RMB with 15.03% for antidepressant medications and 66.45% for non-drug 
medical costs. ConClusions: In Beijing China, most MDD patients also had co-
morbid conditions and were mainly treated in the outpatient setting. SSRIs were 
the most commonly used antidepressants. The economic burden of MDD was 
considerable.
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objeCtives: Atomoxetine is the first medication to receive marketing authoriza-
tion in Spain for the treatment of newly diagnosed adults with Attention-Deficit/
Hyperactivity Disorder (ADHD). The aim of this analysis was to assess if treat-
ment with atomoxetine in adults with ADHD was cost-effective vs. placebo from 
the Spanish Healthcare System perspective. Methods: A Markov state tran-
sition model was developed for a theoretical cohort of newly diagnosed adult 
patients with moderate-severe ADHD. Key input data (response and discon-
tinuation) were derived from the atomoxetine trial program. Patients enter the 
model at the age of 18 and receive atomoxetine (initiated at 40mg for a week and 
then titrated to 80mg or 100mg) or placebo (in the absence of another authorized 
medication for the treatment of newly diagnosed adults with ADHD). Treatment 
success has been defined as response to treatment, showing improvements in 
both symptoms and functioning as measured by the CAARS and CGI-S scales, 
respectively. Treatment, non-specific health state utilities were populated with 
estimates from a vignette study in adults conducted in the UK. Drug and direct 
medical costs were obtained from local databases. In accordance with other 
published ADHD models, a 1-year time horizon was used. To check the model 
for robustness, probabilistic and deterministic sensitivity analyses were per-
formed. Results: Atomoxetine was found to be cost-effective with an ICER of 
€ 24,248/QALY despite patients in placebo arm only accumulating cost of physician 
visits. In addition, a QALY gain of 0.023 was projected, due to greater proportion 
of patients responding to treatment in the atomoxetine arm. Results from a 
probabilistic sensitivity analysis indicated that atomoxetine has a 57% probabil-
ity of being more cost-effective than placebo at a willingness to pay threshold 
of € 30,000/QALY in the Spanish setting. ConClusions: Atomoxetine is a cost-
effective option versus no active medical treatment for newly diagnosed adults 
with ADHD in Spain.
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objeCtives: Schizophrenia is a heterogeneous chronic disease with enormous 
economic consequences for the society. This study aimed at building a conceptual 
framework to evaluate the cost-effectiveness of Aripiprazole Once-Monthly (AOM) 
versus other atypical long-acting injectable (LAI) antipsychotics: Risperidone LAI 
(RLAI), Paliperidone Palmitate (PP) and Olanzapine Pamoate (OP) in the mainte-
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objeCtives: The objectives of this study are to estimate the prevalence of schizo-
phrenia in Switzerland and to assess its burden on patients, caregivers and society 
as a whole. Methods: A hospital registry was combined with a physician survey 
and health insurance claims data to capture all patients living in the northern part 
of the canton of Zurich. Total costs included direct medical and non-medical costs 
and lost production. All costs were calculated for the year 2012 from a societal 
perspective using a prevalence-based bottom-up approach. Intangible costs were 
expressed as quality adjusted life years (QALY) lost and were calculated from Swiss 
life tables, standardized mortality ratios and utility weights from the literature. 
Uncertainty and its sources were addressed in univariate and probabilistic sensi-
tivity analysis. Results: The point prevalence of schizophrenia in 2012 was esti-
mated at 0.39% of the Swiss population. The average annual costs of schizophrenia 
amounted to EUR 39,408 per patient and consisted of direct medical costs of EUR 
9,507 (24%), the costs of care by relatives and in residential homes of EUR 4,793 
(12%) and lost production of EUR 25,108 (64%). Inpatient hospital care accounted 
for EUR 6,242 per year or 66% of direct medical costs. The estimated reduction in 
life expectancy of 10.46 years and the utility decrement of 22.05 percentage points 
lead to intangible costs of 19.02 QALY per incident chronic case. ConClusions: 
The results of this study show the high burden of schizophrenia on patients, caregiv-
ers and society as a whole. The high costs of inpatient hospital care demonstrate 
the benefits of an effective prevention of relapse associated with hospitalization. 
Programs for the reintegration of schizophrenic patients into the labor market have 
a high potential to reduce the costs of schizophrenia considering the high burden 
of lost production and the early onset of the disease.
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objeCtives: Prescription opioid (“RxO”) abuse has not been regarded as a major 
problem in Europe so far, but a lack of reliable data hinders the assessment of this 
problem. This study aimed to derive estimates of the prevalence and excess costs 
of RxO abuse in the five largest European countries (France, Germany, Italy, Spain, 
and UK; “EU5”). Methods: Data from the European Monitoring Centre for Drugs 
and Drug Addiction and the UN Office on Drugs and Crime, on the prevalence of 
problem opioid abuse and the share of opioid abuse patients who report using 
non-heroin opioids, were used to estimate the prevalence of RxO abuse in the EU5. 
The costs of RxO abuse were calculated by applying published estimates of the 
excess health care costs of RxO abuse to country-specific estimates on the costs 
of chronic pain. Sensitivity analyses varied assumptions surrounding the preva-
lence of opioid abuse patients in the general population and the estimates of the 
excess costs of RxO abuse in the EU5. Results: The prevalence of RxO abuse, in 
the general population, varied between the EU5 countries, ranging from 0.7 per 
10,000 to 13.7 per 10,000. In the base case scenario, the total annual health system 
costs of RxO abuse across all EU5 countries were estimated to be € 323 million; results 
of sensitivity analyses ranged from € 98 million to € 730 million. These cost estimates 
included health system costs only; indirect costs were not included. ConClusions: 
RxO abuse imposes a burden on EU5 health systems. Future research should exam-
ine trends in the prevalence and total economic burden of RxO abuse in Europe 
over time and assess the potential benefits of abuse-deterrent formulations, which 
published research suggests have been associated with a significant relative reduc-
tion in rates of diagnosed opioid abuse.
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objeCtives: This study aimed to understand the impact of providing care for 
adults with schizophrenia on productivity, daily activities and resource utilization 
in the 5EU. Methods: Data from the 2010-2011 and 2013 5EU (France, Germany 
Italy, Spain, UK) National Health and Wellness Survey, an online questionnaire 
of a nationwide sample of adults (18+ years) was analyzed. Schizophrenia 
caregivers (n= 398) were matched to non-caregivers (n= 158,989) and other car-
egivers (n= 14,341) on baseline characteristics (sociodemographics, BMI, comor-
bid status) via propensity scores (1: 2). Outcome measures included health care 
utilization (type/number of resources used within the past 6 months) and Work 
Productivity and Activity Impairment questionnaire-based scores. Chi-square 
tests and ANOVAs were used to determine significant differences between 
schizophrenia caregivers vs. non-caregivers and other caregivers (e. g., cancer, 
Alzheimer’s). Results: The average age of schizophrenia caregivers was 45.3 
(SD= 15.8 years), 59.6% were female, and 52.5% were currently employed. After 
matching, schizophrenia caregivers reported greater activity impairment (38.4% 
vs. 26.1%), more health care provider visits (8.0 vs. 5.7), emergency room visits 
(0.9 vs. 0.2) and hospitalizations (0.8 vs. 0.1) than non-caregivers, all p< 0.001. 
Amongst employed respondents, schizophrenia caregivers reported greater 
absenteeism (12.4% vs. 5.6%), presenteeism (29.9% vs. 17.5%), and overall work 
impairment (35.0% vs. 20.7%) than non-caregivers, all p< 0.001. Comparing schizo-
phrenia caregivers and other caregivers, schizophrenia caregivers reported more 
activity impairment (38.4% vs. 32.3%) and health care provider visits (8.0 vs. 
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objeCtives: Attention-deficit/hyperactivity disorder (ADHD) can have a significant 
negative impact on health outcomes in adults. This study was designed, in part, to 
determine the functional outcomes and health care utilization of adult psychiat-
ric outpatients with ADHD in several European countries. Methods: This was a 
multinational observational study. All eligible outpatients (excluding patients with 
any psychotic disorder) from a variety of outpatient settings were invited to partici-
pate. ADHD diagnosis was established with the Diagnostic Interview for ADHD in 
Adults (DIVA) based on the Diagnostic and Statistical Manual of Mental Disorders, 
5thEdition. All patients were further evaluated with the Sheehan Disability Scale 
(SDS) and the EuroQol-5 Dimensions (EQ-5D) questionnaire, which was also used 
to assess anxiety/depression. Results: Of 5662 patients approached, 2284 (40.3%) 
enrolled, of whom 1986 patients (87.0%) completed the study. Patients were 17 to 
72 (median= 42) years of age, and the majority were women (58.8%). Based on the 
DIVA, 17.4% (95% CI 15.7%-19.0%) of patients were diagnosed with ADHD. Patients 
with ADHD had moderate to severe overall impairment (mean SDS total score 18.9 
[SD= 6.6, n= 348] versus 11.6 [SD= 8.6, n= 1659] in patients without ADHD). On the 
EQ-5D, a majority of patients with ADHD indicated having problems performing 
their usual activities (66.2% versus 41.2%) and many reported being “extremely 
anxious or depressed” (24.6% versus 16.0%). However, compared to patients without 
ADHD (n= 1660), patients with ADHD (n= 349) were less often prescribed antide-
pressants (57% versus 71.9%). The proportions of patients who visited a primary 
care physician, psychiatrist, or psychotherapist during the previous 6 months were 
similar between the 2 groups. ConClusions: Adult psychiatric outpatients with 
ADHD in our sample reported more overall functional impairment and psychiatric 
comorbidities compared to outpatients without ADHD. The use of medical resources 
was similar between the 2 groups.
PMH29
PaliPeridone versUs atyPical long-acting antiPsycHotics for 
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objeCtives: To determine the cost-effectiveness of atypical long-acting injectable 
(LAI) antipsychotics in treating relapsed chronic schizophrenia from the viewpoint 
of the Finnish National Health Service. Methods: A 1-year decision tree was 
adapted for use with patients in relapse, guided by an expert panel. Drugs included 
available atypical long-acting antipsychotics: paliperidone (PP-LAI), risperidone 
(RIS-LAI), olanzapine (OLZ-LAI) and aripiprazole (ARI-LAI). Rates of adherence, 
success, relapse and hospitalization were taken from the literature. Prices were 
obtained from standard lists and expressed in 2014 euros: drugs, psychiatrists/
physicians, psychiatric nurse, inpatient and outpatient hospital care. Outcomes 
included expected cost/patient treated, QALYs, rates of re-hospitalization, emer-
gency room (ER) visits and days in relapse. The primary analysis was the incre-
mental cost per QALY. These preliminary results were tested with 1-way sensitivity 
analyses on important inputs. Results: Over the 1-year time horizon, PP-LAI 
had the lowest total cost of 34,446€ per patient, RIS-LAI cost 37,338€ , ARI-LAI cost 
37,433€ and OLZ-LAI cost 41,384€ . PP-LAI had the highest number of QALYs (0.686), 
followed by OLZ-LAI with 0.680, RIS-LAI with 0.674 and ARI-LAI with 0.671. PP-LAI 
also had the lowest rates of all negative outcomes. Re-hospitalization rates were 
10.1%, 12.5%, 12.4% and 12.2% for PP-LAI, RIS-LAI, ARI-LAI and OLZ-LAI, respec-
tively, Respective ER visits were 20.6%, 23.2%, 25.4% and 21.7%. Patients receiving 
PP-LAI experienced 224.0 relapse days, as opposed to 234.8 with RIS-LAI, 237.5 
with ARI-LAI and 234.8 with OLZ-LAI. In 1-way sensitivity analyses, costs were 
robust (required changes > 20%) against changes in drug price, primary rate of 
success, rates of relapse, dropouts and adherence. The driver of the model for 
all drugs was hospitalization, comprising from 70%-81% of the total cost; drug 
costs constituted 12%-22% and medical care 8%-15%. ConClusions: PP-LAI was 
shown to have the lowest cost and best clinical outcomes, and hence should be 
the atypical LAI of choice.
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objeCtives: Art therapy provides an alternative to standard forms of psychological 
therapy. We estimated the cost-effectiveness of group art therapy for people with 
non-psychotic mental disorders. Methods: A de novo area under the curve model 
was constructed with the following assumptions that: the maximum treatment 
effect would be associated with the time at which treatment ended; there would 
be a linear increase in treatment effect, from zero at baseline to the time at which 
treatment ended; there would be a residual effect of treatment with a linear decline 
in benefit until there was zero benefit at 52 weeks; given the short assumed duration 
of benefit, discounting was not necessary. Two RCTs identified in an accompanying 
clinical review provided data from which EQ-5D values could be estimated via map-
ping allowing comparisons to be made of group art therapy with wait-list control 
and with group verbal therapy. Scenario analyses altering the cost per patient and 
the assumed residual benefit were conducted. Results: Art therapy compared 
with wait-list control had a mean cost per quality adjusted life year (QALY) below 
nance treatment of schizophrenia. Methods: The schizophrenia Markov model 
developed by the National Institute for Health and Care Excellence (NICE) was 
adapted to the context of LAI antipsychotics. Effectiveness was measured through 
Quality-Adjusted Life Years (QALYs) and number of relapses. The economic anal-
ysis was conducted over a ten-year time horizon, including cost of managing 
stable schizophrenia, relapse and treatment-emergent adverse events (TEAEs). 
Probabilities of relapse, discontinuation due to adverse events, and due to other 
reasons came from a mixed treatment comparison of pivotal clinical trials; disu-
tilities associated to TEAEs and other non-drug-specific inputs came from various 
epidemiological sources. Results: AOM was associated with higher number of 
QALYs (7.26 vs 7.17, 7.18 & 7.19 for PP, RLAI and OP respectively) over a 10-year time 
horizon. Assuming a theoretical parity price between AOM and PP, the base case 
analysis showed that AOM was the dominant strategy as compared to RLAI, PP and 
OP. Deterministic sensitivity analyses confirmed these overall Conclusions, the 
main drivers of cost-effectiveness being both probability and cost of relapse. In the 
probabilistic sensitivity analysis, AOM demonstrated a higher probability of being 
cost-effectiveness than RLAI, PP and OP at a willingness to pay threshold of £20,000 
(52%, 89% and 90%, respectively). ConClusions: Although model outcome may 
vary according to local data and settings, and assuming a theoretical parity price 
with PP, AOM was found to provide clinical benefits at lower total costs compared 
to other atypical LAI antipsychotics, showing its value in the maintenance treat-
ment of schizophrenia.
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objeCtives: Aim to determine the most cost-effective threshold of depression 
severity above which to prescribe anti-depressants to patients, in England and 
Wales, presenting with depression and under consideration for anti-depressants. 
Also aim to evaluate the cost-effectiveness of a new trial of anti-depressants 
in a population of wider range of depression severity than in previous tri-
als. Methods: Meta-regression of existing study results to estimate a propor-
tional treatment effect on depression severity, which is then extrapolated to a 
wider range of severity than in included trials. An economic model which con-
sists of a continuous outcome for the initial 12 weeks of treatment, followed by 
a Markov model with states for depression category and treatment. Treatment 
effects on Hamilton Depression Rating Scale (HAMD) were mapped to EQ5D. 
Expected value of partial perfect information (EVPPI) was used to determine an 
upper bound on the value of collecting ffurther evidence. Results: Patients on 
anti-depressants had an additional 12% (CrI 3-21%) decrease in 6-week HAMD 
versus placebo. Treating patients with a severity > 2 on HAMD had the highest 
probability (> 65%) of being cost-effective at £20,000 willingness-to-pay thresh-
old. However this assumes that the relationship with severity can be extrapo-
lated beyond the range of HAMD included in the systematic review. A short-term 
trial investigating the relation between treatment effect and severity and qual-
ity of life in depression patients had EVPPI= £67.7 million over a 10 year time-
horizon. ConClusions: On the basis of available evidence, our model suggests 
it may be cost-effective to treat patients with lower severity of symptoms than 
have been included in the majority of existing RCTs. However, evidence of treat-
ment efficacy in those with low HAMD is lacking, and there is likely to be value in 
conducting a trial on this lower severity population.
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objeCtives: To assess, from the perspective of national health insurance, the 
cost-effectiveness of psychosocial support plus nalmefene versus psychosocial 
support alone, for the treatment of adult patients with alcohol dependence who 
have a high drinking risk level, without physical withdrawal symptoms, and who 
do not require immediate detoxification. Methods: A cost-effectiveness Markov 
model, originally developed for the Single Technology Appraisal by the National 
Institute for Health and Care Excellence of Nalmefene, was adapted to the Greek 
health care setting to evaluate the health effects and associated costs of compared 
therapeutic options. The model consisted of a short-term phase (1 year: based on 
clinical trials assessing nalmefene) and a long-term phase (2-5 years) evaluat-
ing patient progression and a second-line abstinence treatment option. Clinical 
inputs were derived from ESENSE1 (NCT00811720), ESENSE2 (NCT00812461) and 
SENSE (NCT00811941) clinical trials and epidemiological data from the national 
statistical authority and published literature. All direct costs with respect to treat-
ment of alcohol dependence and the management of alcohol-attributable harmful 
events were considered reflecting the year 2014. Results: Over a 5-year hori-
zon, the addition of nalmefene to psychosocial support led to the avoidance of 
3,071 alcohol-attributable diseases/injuries and 851 deaths per 100,000 patients. 
Nalmefene plus psychosocial support reduced the proportion of high-risk and 
very high-risk drinkers (23% versus 37% with psychosocial support alone) and 
increased the number of controlled drinkers (61% versus 45%). In the base-case, 
the nalmefene plus psychosocial support arm cumulated a 5-year incremental 
cost of € 160 and an incremental QALY of 0.024. The incremental cost-effectiveness 
ratio of € 1,928 was considerably low with respect to the decision threshold of 
€ 16,000 per QALY gained (equal to the GDP per capita of Greece). ConClusions: 
Treatment with nalmefene is cost-effective in the Greek health care setting leading 
to significant reductions of alcohol dependent patients and alcohol-attributable 
harmful events.
